Clinical results for Episealer® to be presented at orthopedic congress in Germany

Episurf Medical (Nasdaq: EPIS B) today announces that its implant technology and clinical results from the use of the Episealer® implant will be presented at the German workgroup for Arthroplasty’s 21st annual meeting in Düsseldorf, 6-7 December. 

Dr. med. J. Holz has been invited to the meeting to hold a presentation on the topic “Small Implants – zu selten indiziert?”. The presentation is based on the clinical results from a European multicenter study with 100 patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects using the knee implant Episealer®. The study shows excellent early clinical results from the treatment of focal symptomatic cartilage lesions on the femoral condyles and the trochlea area in the knee joint.

“We appreciate the continued strong interest in our treatment alternative Episealer®, and we appreciate that an increasing number of clinics in Germany are starting to offer our technology to their patients,” says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags:

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.